Idelalisib Recruiting Phase 2 Trials for Amyloidosis Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02590588Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis